Clinical Focus

• Cancer> Blood and Marrow Transplant
• Cancer> Hematology
• Blood and Marrow Transplantation
• Hematology

Professional Education

Current Research Interests

Dr. Lowsky's research is focused on understanding the role of regulatory T cells in the prevention of GVHD and in promoting immune tolerance following organ transplantation.

Clinical Trials

• Allogeneic HCT using Nonmyeloablative Host Conditioning with TLI & ATG vs SOC in AML Recruiting
• Allogeneic Transplantation Using TL1 & ATG for Older Patients with Hematologic Malignancies Recruiting
• Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies Recruiting
• TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD Recruiting
• A Phase 3 Study of Brentuximab Vedotin (SGN-35) for Prevention of Hodgkin Lymphoma Progression (The AETHERA Trial) Recruiting

Publications

• Prophylactic rituximab after allogeneic transplantation decreases B cell alloimmunity with low chronic GVHD incidence. Arai S, Sahaf B, Narasimhan B, Chen GL, Jones CD, Lowsky R, Shizuru JA, Johnston LJ, Laport GG, Weng WK, Benjamin JE, Schaenman J, Brown J, Ramirez J, Zehnder JL, Negrin RS, Miklos DB. Blood. 2012
• Tolerance and Withdrawal of Immunosuppressive Drugs in Patients Given Kidney and Hematopoietic Cell Transplants. Scandling JD, Busque S, Dejbakhsh-Jones S, Benike C, Sarwal M, Millan MT, Shizuru JA, Lowsky R, Engleman EG, Strober S. Am J Transplant. 2012
• Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Laport GG, Sheehan K, Baker J, Armstrong R, Wong RM, Lowsky R, Johnston LJ, Shizuru JA, Miklos D, Arai S, Benjamin JE, Weng WK, Negrin RS. Biol Blood Marrow Transplant. 2011; 17 (11): 1679-87
• Donor immunization with WT1 peptide augments antileukemic activity after MHC-matched bone marrow transplantation. Kohrt HE, Müller A, Baker J, Goldstein MJ, Newell E, Dutt S, Czerwinski D, Lowsky R, Strober S. Blood. 2011; 118 (19): 5319-29
• Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY. Naik S, Wong R, Arai S, Brown J, Laport G, Lowsky R, Miklos D, Shizuru J, Blume K, Negrin R, Johnston L. Bone Marrow Transplant. 2011; 46 (2): 192-9